Innovation1 Biotech Total Debt vs. Current Ratio
| IVBT Stock | USD 0 0.00 0.00% |
For Innovation1 Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Innovation1 Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Innovation1 Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Innovation1 Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Innovation1 Biotech over time as well as its relative position and ranking within its peers.
Innovation1 |
Innovation1 Biotech Current Ratio vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Innovation1 Biotech's current stock value. Our valuation model uses many indicators to compare Innovation1 Biotech value to that of its competitors to determine the firm's financial worth. Innovation1 Biotech is considered the number one company in total debt category among its peers. It also is currently regarded as number one stock in current ratio category among its peers . The ratio of Total Debt to Current Ratio for Innovation1 Biotech is about 18,480,000 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innovation1 Biotech's earnings, one of the primary drivers of an investment's value.Innovation1 Total Debt vs. Competition
Innovation1 Biotech is considered the number one company in total debt category among its peers. Total debt of Biotechnology industry is currently estimated at about 220.32 Million. Innovation1 Biotech adds roughly 554,400 in total debt claiming only tiny portion of stocks in Biotechnology industry.
Innovation1 Current Ratio vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Innovation1 Biotech |
| = | 554.4 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Innovation1 Biotech |
| = | 0.03 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Innovation1 Current Ratio Comparison
Innovation1 Biotech is currently under evaluation in current ratio category among its peers.
Innovation1 Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Innovation1 Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Innovation1 Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Innovation1 Biotech's change in net profit over the period of time. It can combine multiple indicators of Innovation1 Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Innovation1 Biotech Inc. operates as a small molecule drug discovery company. The company was founded in 2014 and is based in New York, New York. Innovation1 Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Innovation1 Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Innovation1 Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Innovation1 Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Innovation1 Biotech's important profitability drivers and their relationship over time.
Use Innovation1 Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Innovation1 Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innovation1 Biotech will appreciate offsetting losses from the drop in the long position's value.Innovation1 Biotech Pair Trading
Innovation1 Biotech Pair Trading Analysis
The ability to find closely correlated positions to Innovation1 Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Innovation1 Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Innovation1 Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Innovation1 Biotech to buy it.
The correlation of Innovation1 Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Innovation1 Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Innovation1 Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Innovation1 Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Innovation1 Biotech position
In addition to having Innovation1 Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Giant Impact Thematic Idea Now
Giant Impact
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.